Relationship of Different Electrocardiographic Parameters and Ambulatory Blood Pressure Parameters to Detect Left Ventricular Hypertrophy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03542526 |
|
Recruitment Status :
Recruiting
First Posted : May 31, 2018
Last Update Posted : May 31, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment |
|---|---|
| Hypertension | Device: electrogradiogram Device: ambulatory blood prussre |
Arterial hypertension is a major cause of coronary heart disease, stroke, and heart failure. Several studies have shown that left ventricular hypertrophy is an important risk factor in patients with hypertension, leading to a fivefold to 10-fold increase in cardiovascular risk,1 2 3 4 5 which is similar to the increase seen in patients with a history of myocardial infarction.6 The presence of left ventricular hypertrophy, in addition to hypertension, thus has important implications for assessing risk and managing patients, including decisions on interventions other than antihypertensive treatment, such as lipid lowering treatment and lifestyle modifications.7 8 Accurate and early diagnosis of left ventricular hypertrophy is therefore an important component of the care of patients with hypertension.
Decisions about treatment should be based on assessments of hypertensive target organ damage and overall cardiovascular risk. The appropriate diagnostic work-up of suspected left ventricular hypertrophy in patients with hypertension is less clear, however. There is many electrocardiographic indexes for the diagnosis of left ventricular hypertrophy, based on the standard 12 lead electrocardiogram, have been described. Many of the proposed indexes have remained anecdotal, but others are commonly used, including the Sokolow-Lyon index,9 the Cornell voltage index,10 the Cornell product index,11 the Gubner index,12 and the Romhilt-Estes scores.13 However, debate about their comparative diagnostic value continues.14 15 We did a systematic review to clarify the accuracy of different electrocardiographic indexes, with emphasis on their ability to rule out left ventricular hypertrophy in patients with arterial hypertension.
| Study Type : | Observational |
| Estimated Enrollment : | 73 participants |
| Observational Model: | Case-Control |
| Time Perspective: | Cross-Sectional |
| Official Title: | Relationship of Different Electrocardiographic Parameters and Ambulatory Blood Pressure Parameters to Detect Left Ventricular Hypertrophy |
| Estimated Study Start Date : | January 1, 2019 |
| Estimated Primary Completion Date : | December 31, 2020 |
| Estimated Study Completion Date : | December 31, 2022 |
- Device: electrogradiogram
12 lead ecg ambulatory blood prussreOther Name: blood measuring device
- Device: ambulatory blood prussre
ambulatory blood pressure to measure blood pressure
- minimize complicate of hypertension [ Time Frame: 1 years ]screening with hypertensive patient
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Inclusion Criteria:
Patients ranging from 20t o 80 years attending the hypertension outpatient clinic for ambulatory blood pressure measurement will be consecutively enrolled
Exclusion Criteria:
- Patients with ischemic heart disease.
- Patients with advanced respiratory, renal, or hepatic disease
- Patients with uninterpretable ECG or ABPM recordings
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03542526
| Contact: Yehia t Keshk, professor | 20882335120 | yehia@aun.edu.eg | |
| Contact: Tarek a nagib, lecturer | 201099975128 | Tarkaf76@yahoo.com |
| Egypt | |
| AssiutU | Recruiting |
| Assiut, Egypt | |
| Contact: Yehia T Keshk, professor 20882335120 yehia@aun.edu.eg | |
| Contact: Tarek a nagib, lecturer 201099975128 Tarkaf76@yahoo.com | |
Publications:
| Responsible Party: | Michael Sadeq, cardiology resident, principle investigator, Assiut University |
| ClinicalTrials.gov Identifier: | NCT03542526 |
| Other Study ID Numbers: |
LVHTN |
| First Posted: | May 31, 2018 Key Record Dates |
| Last Update Posted: | May 31, 2018 |
| Last Verified: | May 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Plan Description: | to maintain the privacy of the protocol |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Hypertrophy, Left Ventricular Hypertrophy Cardiovascular Diseases |
Pathological Conditions, Anatomical Cardiomegaly Heart Diseases |